Table 8: Comparison of HbA1c and blood pressures in treatment group and placebo group between baseline, at three-months treatment, and at six- to nine-months washout.
Parameters |
Treatment group (n = 12) |
Placebo group (n = 18) |
||||
Mean ± SD |
F |
P-value |
Mean ± SD |
F |
P-value |
|
HbA1c (%) |
|
|
|
|
|
|
Baseline |
9.30 ± 2.09 |
3.150 |
0.063 |
8.52 ± 1.73 |
0.512 |
0.604 |
Week 12 |
8.90 ± 1.47 |
|
|
8.44 ± 1.80 |
|
|
Week 36 |
8.58 ± 1.46 |
|
|
8.25 ± 1.32 |
|
|
SBP (mmHg) |
|
|
|
|
|
|
Baseline |
138.72 ± 16.05 |
1.329 |
0.285 |
135.37 ± 10.19 |
1.937 |
0.160 |
Week 12 |
131.94 ± 10.03 |
|
|
131.15 ± 11.20 |
|
|
Week 36 |
132.17 ± 12.71 |
|
|
138.00 ± 14.96 |
|
|
DBP (mmHg) |
|
|
|
|
|
|
Baseline |
75.60 ± 7.83 |
1.532 |
0.238 |
77.97 ± 7.18 |
2.225 |
0.124 |
Week 12 |
72.56 ± 11.20 |
|
|
75.34 ± 8.61 |
|
|
Week 36 |
77.08 ± 11.54 |
|
|
78.96 ± 9.24 |
|
|
Repeated measures ANOVA. Assumptions fulfilled. n: number of patients; HbA1c: Haemoglobin A1c; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; Week 12: at 12 weeks of treatment; Week 36: 24 weeks after treatment cessation.